Pall and Cytiva join forces

Cytiva and Pall Life Sciences complete integration to create a global innovation and solutions leader in biotechnology

02-May-2023 - Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand. With nearly 16 000 associates in 40 countries, and more than 300 years' heritage of trusted expertise, the new Cytiva supports customers in solving ...

Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions

Major investments are expanding manufacturing capacity for life sciences products at 13 Cytiva and Pall Corporation sites helping to meet customer demand.

03-Aug-2021 - An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers. The investment, already underway, includes new sites, expansion at existing factories, and is ...

Cytiva acquires Intermountain Life Sciences

Double capacity for buffers and liquid cell culture media

02-Jul-2021 - Cytiva has acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell culture media. Cytiva will use Intermountain’s manufacturing site in Utah to rapidly boost its liquid cell culture production by millions of liters. Hiring is ongoing to rapidly increase ...

Introducing Cytiva

Previously GE Healthcare Life Sciences, Cytiva will help accelerate growth and innovation in biological therapies

01-Apr-2020 - Cytiva, a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics, launches. Previously GE Healthcare Life Sciences, Cytiva has nearly 7,000 employees and operations in 40 countries and is part of the Danaher Corporation Life ...

GE Healthcare Life Sciences plans new manufacturing facility in Switzerland

21-Jan-2020 - GE Healthcare Life Sciences is building a new 7,360 square meter facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single use kits for the Sepax and Sefia cell processing systems. The facility will meet global regulatory requirements and is expected to be fully ...

GE Healthcare acquires bioprocessing start-up

Obtaining nanofiber-based platform purification technology for biopharmaceutical production

30-Nov-2017 - GE Healthcare has completed the acquisition of Puridify, a bioprocessing start-up that is developing a nanofiber-based platform purification technology for biopharmaceutical production. Puridify’s technology, FibroSelect, is complementary to the bead resins and chromatography membranes used today ...

GE Healthcare expands European capabilities to support accelerated biomanufacturing

Rapid Response Production service for research, process development, and bioproduction launched

13-Apr-2016 - GE Healthcare’s Life Sciences business announced that its European manufacturing and distribution site for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids and cell culture media, and launched a rapid production service for prototype ...

GE Healthcare and Takeda Join Forces to Develop Therapeutic Drugs to Target Liver Diseases

13-Nov-2014 - GE Healthcare and Takeda Pharmaceutical Company announced that they have entered into an alliance agreement for research and development in the field of hepatic fibrosis, a key factor in the diagnosis and treatment of liver diseases. Liver disease has almost no visible symptoms, and its progress ...

CEVEC and Vakzine Projekt Management: License Agreement on the Clinical Development of Cytomegalovirus Vaccine

08-Jan-2013 - CEVEC Pharmaceuticals (CEVEC), the developer of the CAP® Technology, a novel human expression system derived from amniocytes, and VPM – Vakzine Projekt Management GmbH announced the signing of an license agreement on VPM’s proprietary human CMV dense body technology. CAP® Technology is based on ...

GE Healthcare and BAC collaborate to launch new bioprocess affinity resin

21-Mar-2012 - GE Healthcare and BAC BV announced that, following a successful collaboration between the two companies, GE Healthcare Life Sciences has added a new affinity resin to its portfolio of technologies for the purification of antibody-based fragments. GE Healthcare’s new resin, LambdaFabSelect, is a ...